David V Glidden1, Kathleen Mulligan1, Vanessa McMahan2, Peter L Anderson3, Juan Guanira4, Suwat Chariyalertsak5, Susan P Buchbinder1,6, Linda-Gail Bekker1,7, Mauro Schechter8, Beatriz Grinsztejn9, Robert M Grant10,11. 1. University of California, San Francisco. 2. University of Washington, Seattle. 3. University of Colorado, Denver, Aurora. 4. Investigaciones Médicas en Salud, Lima, Peru. 5. Research Institute for Health Sciences, Chiang Mai University, Thailand. 6. Bridge HIV, San Francisco Department of Public Health, California. 7. Desmond Tutu HIV Foundation, Cape Town, South Africa. 8. Projeto Praça Onze, Hospital Escola São Francisco de Assis and Universidade Federal do Rio de Janeiro. 9. Evandro Chagas National Institute of Infectious Diseases-Fiocruz, Rio de Janeiro, Brazil. 10. Gladstone Institute of Virology, California. 11. San Francisco AIDS Foundation, California.
Abstract
Background: Antiretroviral drugs have been associated with changes in lipids, fat mass and dat distribution. Tenofovir disoproxil fumarate (TDF) has been shown to have a more favorable metabolic profile than other drugs in its class. However, the metabolic effects of TDF in preexposure prophylaxis (PrEP) are unknown. Methods: We evaluated the effects of TDF/emtricitabine (FTC) on lipids and body composition in a blinded, placebo-controlled PrEP trial. Participants enrolled in a metabolic subcohort (N = 251, TDF/FTC; N = 247, placebo) consented to fasting lipid panels, dual-energy X-ray absorptiometry scans for body composition, and pharmacologic testing of drug metabolites at baseline and every 24 weeks thereafter. Results:Lean body mass was stable and unaffected by TDF/FTC. Body weight increased in both groups but was lower on TDF/FTC through week 72. This difference was explained by lower fat accumulation on TDF/FTC. The net median percent difference (standard error, P value) for TDF/FTC vs placebo at week 24 was -0.8% (0.4%, P = .02), +0.3% (0.4%, P = .46), and -3.8% (1.4%, P = .009) for total, lean, and fat mass, respectively. There was no apparent differential regional fat accumulation on TDF/FTC. Decreases in cholesterol, but not triglycerides, were seen in TDF/FTC participants, with detectable drug levels compared to placebo. Conclusions: TDF/FTC for PrEP showed cholesterol reductions and appeared to transiently suppress the accumulation of weight and body fat compared to placebo. There was no evidence of altered fat distribution or lipodystrophy during daily oral TDF/FTC PrEP. Clinical Trials Registration: NCT00458393.
RCT Entities:
Background: Antiretroviral drugs have been associated with changes in lipids, fat mass and dat distribution. Tenofovir disoproxil fumarate (TDF) has been shown to have a more favorable metabolic profile than other drugs in its class. However, the metabolic effects of TDF in preexposure prophylaxis (PrEP) are unknown. Methods: We evaluated the effects of TDF/emtricitabine (FTC) on lipids and body composition in a blinded, placebo-controlled PrEP trial. Participants enrolled in a metabolic subcohort (N = 251, TDF/FTC; N = 247, placebo) consented to fasting lipid panels, dual-energy X-ray absorptiometry scans for body composition, and pharmacologic testing of drug metabolites at baseline and every 24 weeks thereafter. Results: Lean body mass was stable and unaffected by TDF/FTC. Body weight increased in both groups but was lower on TDF/FTC through week 72. This difference was explained by lower fat accumulation on TDF/FTC. The net median percent difference (standard error, P value) for TDF/FTC vs placebo at week 24 was -0.8% (0.4%, P = .02), +0.3% (0.4%, P = .46), and -3.8% (1.4%, P = .009) for total, lean, and fat mass, respectively. There was no apparent differential regional fat accumulation on TDF/FTC. Decreases in cholesterol, but not triglycerides, were seen in TDF/FTC participants, with detectable drug levels compared to placebo. Conclusions: TDF/FTC for PrEP showed cholesterol reductions and appeared to transiently suppress the accumulation of weight and body fat compared to placebo. There was no evidence of altered fat distribution or lipodystrophy during daily oral TDF/FTC PrEP. Clinical Trials Registration: NCT00458393.
Authors: Jane E Mallewa; Edmund Wilkins; Javier Vilar; Macpherson Mallewa; Dominic Doran; David Back; Munir Pirmohamed Journal: J Antimicrob Chemother Date: 2008-06-18 Impact factor: 5.790
Authors: Robert M Grant; Peter L Anderson; Vanessa McMahan; Albert Liu; K Rivet Amico; Megha Mehrotra; Sybil Hosek; Carlos Mosquera; Martin Casapia; Orlando Montoya; Susan Buchbinder; Valdilea G Veloso; Kenneth Mayer; Suwat Chariyalertsak; Linda-Gail Bekker; Esper G Kallas; Mauro Schechter; Juan Guanira; Lane Bushman; David N Burns; James F Rooney; David V Glidden Journal: Lancet Infect Dis Date: 2014-07-22 Impact factor: 25.071
Authors: Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Penny Gordon-Larsen; Ningqi Hou; Steve Sidney; Barbara Sternfeld; Cora E Lewis; David R Jacobs; Barry M Popkin Journal: Am J Clin Nutr Date: 2008-12-03 Impact factor: 7.045
Authors: Ana Milinkovic; Esteban Martinez; Sonia López; Elisa de Lazzari; Oscar Miró; Sergi Vidal; José L Blanco; Gloria Garrabou; Montserrat Laguno; Joan A Arnaiz; Agathe Leon; Maria Larrousse; Montserrat Lonca; Josep Mallolas; José M Gatell Journal: Antivir Ther Date: 2007
Authors: José R Valdez Madruga; Isabel Cassetti; Jamal Muhamad A H Suleiman; Arnaldo Etzel; Lijie Zhong; Charles B Holmes; Andrew K Cheng; Jeffrey Enejosa Journal: HIV Clin Trials Date: 2007 Nov-Dec
Authors: Sheena McCormack; David T Dunn; Monica Desai; David I Dolling; Mitzy Gafos; Richard Gilson; Ann K Sullivan; Amanda Clarke; Iain Reeves; Gabriel Schembri; Nicola Mackie; Christine Bowman; Charles J Lacey; Vanessa Apea; Michael Brady; Julie Fox; Stephen Taylor; Simone Antonucci; Saye H Khoo; James Rooney; Anthony Nardone; Martin Fisher; Alan McOwan; Andrew N Phillips; Anne M Johnson; Brian Gazzard; Owen N Gill Journal: Lancet Date: 2015-09-09 Impact factor: 79.321
Authors: Anthony Mills; Jose R Arribas; Jaime Andrade-Villanueva; Giovanni DiPerri; Jan Van Lunzen; Ellen Koenig; Richard Elion; Matthias Cavassini; Jose Valdez Madruga; Jason Brunetta; David Shamblaw; Edwin DeJesus; Chloe Orkin; David A Wohl; Indira Brar; Jeffrey L Stephens; Pierre-Marie Girard; Gregory Huhn; Andrew Plummer; Ya-Pei Liu; Andrew K Cheng; Scott McCallister Journal: Lancet Infect Dis Date: 2015-11-02 Impact factor: 25.071
Authors: Paul E Sax; Jürgen K Rockstroh; Anne F Luetkemeyer; Yazdan Yazdanpanah; Douglas Ward; Benoit Trottier; Armin Rieger; Hui Liu; Rima Acosta; Sean E Collins; Diana M Brainard; Hal Martin Journal: Clin Infect Dis Date: 2021-07-15 Impact factor: 9.079
Authors: Michael A Leonard; Zinhle Cindi; Yuki Bradford; Kassem Bourgi; John Koethe; Megan Turner; Jamison Norwood; Beverly Woodward; Husamettin Erdem; Rebecca Basham; Paxton Baker; Peter F Rebeiro; Timothy R Sterling; Todd Hulgan; Eric S Daar; Roy Gulick; Sharon A Riddler; Phumla Sinxadi; Marylyn D Ritchie; David W Haas Journal: Clin Infect Dis Date: 2021-10-05 Impact factor: 20.999
Authors: Paul E Sax; Kristine M Erlandson; Jordan E Lake; Grace A Mccomsey; Chloe Orkin; Stefan Esser; Todd T Brown; Jürgen K Rockstroh; Xuelian Wei; Christoph C Carter; Lijie Zhong; Diana M Brainard; Kathleen Melbourne; Moupali Das; Hans-Jürgen Stellbrink; Frank A Post; Laura Waters; John R Koethe Journal: Clin Infect Dis Date: 2020-09-12 Impact factor: 9.079
Authors: Stefan Petkov; Carolina Herrera; Laura Else; Susan Mugaba; Patricia Namubiru; Geoffrey Odoch; Daniel Opoka; Azure-Dee A P Pillay; Thabiso B Seiphetlo; Jennifer Serwanga; Andrew S Ssemata; Pontiano Kaleebu; Emily L Webb; Saye Khoo; Limakatso Lebina; Clive M Gray; Neil Martinson; Julie Fox; Francesca Chiodi Journal: Front Immunol Date: 2022-07-27 Impact factor: 8.786